Annual sport record · O-053
2026 WADA peptide changes
The named S2 change is one added example, not the whole peptide rule. Pegmolesatide now appears as an EPO-mimetic agent, while the List continues to prohibit wider named and unnamed classes.
The 2026 WADA Prohibited List has applied since 1 January 2026. Its peptide-related headline change is the addition of pegmolesatide as an example of an EPO-mimetic agent in S2.1.1. The change clarifies a substance within an already prohibited class; it does not replace the broader class, analogue and similar-effect wording athletes must still check.
What changed for peptide-related substances in 2026
WADA's summary identifies the change; the full List supplies the operative class and examples.
| Section | 2026 change | Effective date | Interpretation |
|---|---|---|---|
| S2.1.1 Erythropoietin-receptor agonists | Pegmolesatide added as an example of an EPO-mimetic agent | 1 January 2026 | An added named example within a class prohibited at all times |
The official summary does not identify a 2026 reclassification of the broader growth-hormone releasing peptide, growth-factor or peptide-hormone categories. Their existing class wording remains operative.
An added example is not the start of the prohibition
S2.1.1 already prohibited erythropoietin-receptor agonists, including EPO-mimetic agents and their constructs. Adding pegmolesatide makes that example explicit. The status does not depend on the word “peptide” in a product description.
The List uses non-exhaustive language such as “including, but not limited to”. It also contains broader similar-structure or similar-effect wording. A substance can therefore be prohibited even when a casual exact-name search returns no match.
Peptide classes that remain important in the 2026 List
This is a route map, not a substitute for checking the full current List and an athlete's anti-doping organisation.
| Section | Examples or scope | Why exact-name search can fail |
|---|---|---|
| S2.2.1 | Testosterone-stimulating peptides in males, including gonadotrophin-releasing hormone agonists and kisspeptin agonists | The rule includes analogues and is sex-specific in this subsection |
| S2.2.3 | Growth hormone, its analogues and fragments, including AOD-9604 and hGH 176-191 | Fragments or analogues may be captured by class |
| S2.2.4 | Growth hormone releasing factors, secretagogues, mimetics and GHRPs | Aliases and class members extend beyond one product label |
| S2.3 | Growth factors and growth-factor modulators, including thymosin beta-4 derivatives such as TB-500 | The listed examples are not exhaustive |
| S4.4.1 | AMPK activators, including MOTS-c | A peptide-related substance may sit outside S2 |
| S0 | Pharmacologically active substances without current approval for human therapeutic use by a governmental regulatory health authority | An investigational substance may be captured without a peptide-specific name |
Re-run the status check for the new List year
Do not carry a 2025 screenshot or database result into 2026 without confirming the edition and class wording.
- Identify the exact substance and aliases.Record salts, fragments, analogues and common code names rather than relying on a seller label.
- Open the 2026 List.Confirm the edition and effective date before searching.
- Search names, then read the class.A nil exact-name result is not clearance when a broader class or catch-all may apply.
- Check the athlete's medicines route.Use Global DRO where available and ask the relevant anti-doping organisation about ambiguity.
- Record the result.Keep the List year, section, match type, source URL and date checked.
Use the annual change with the standing framework
- the sport framework this updatesUnderstand prohibited-at-all-times classes, named examples and catch-all wording.
- re-run your check against the new ListFollow the identity, name, class and record-keeping sequence.
- MOTS-c and the S4 classSee why a peptide-related substance may sit outside S2.
- TB-500 and S2.3Match the product name to thymosin beta-4 derivative wording.
- the annual sport list changesCheck any substantive correction to this record.
Primary source ledger
The List and change summary come from WADA. Supporting national anti-doping pages are used only to make the same official change easier to inspect.
| Source | What it establishes | What it does not establish |
|---|---|---|
| WADA 2026 Prohibited List | The operative classes, examples and 1 January 2026 effective date | A product's true identity or a case-specific anti-doping ruling |
| WADA 2026 Summary of Major Modifications | Pegmolesatide was added as an example of an EPO-mimetic agent | A complete replacement for the full List text |
| WADA publication notice | Publication record and the set of 2026 List materials | Substance-by-substance clearance |
| NADA Germany 2026 changes page | An anti-doping organisation's accessible restatement of the pegmolesatide change | Authority to alter WADA's List |
| Global DRO | A country-specific medicines-checking route for participating jurisdictions | A guarantee about unlisted research chemicals or mislabelled products |
Annual update protocol
WADA publishes a new Prohibited List each year, normally before it takes effect on 1 January. This record is checked when WADA releases the next List, a modification summary or an official correction.
A newly named example may clarify an existing class rather than create a first-time prohibition. We compare both the summary and the full text before changing an affected profile.
2026 WADA List questions
What peptide-related substance was added to the 2026 WADA List?
Pegmolesatide was added as an example of an EPO-mimetic agent in S2.1.1. The class is prohibited at all times.
Was pegmolesatide newly prohibited only from 2026?
WADA's summary describes it as a new named example. Because S2.1.1 already covered EPO-mimetic agents, the safest interpretation is that the addition clarifies the class rather than proving a first-ever prohibition date.
Are all peptides prohibited in sport?
No. “Peptide” is not one universal WADA category. Some substances are named, some are captured by a prohibited class or S0, and some may not be prohibited. The exact substance and current List must be checked.
Does a missing name mean a peptide is permitted?
No. The List uses non-exhaustive class wording and can capture analogues or substances with similar structure or biological effect. Check the full class and seek an authoritative answer when the match is unclear.
When did the 2026 WADA List take effect?
The 2026 Prohibited List took effect on 1 January 2026. A previous edition should not be used for a current status check.
Where should an athlete check a prescribed medicine?
Use Global DRO where it covers the relevant country and sport, then follow the athlete's anti-doping organisation and therapeutic use exemption process. Keep a dated record of the check.
Editorial experience
From our work: how we checked this page
For topical-map item O-053, 2026 WADA Prohibited List peptide changes was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 5 unique external sources and 8 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Yianni Kiromitis checked the page against its mapped purpose, verified the cited sources, reviewed the internal routes and approved the final wording as Lead Author, Publisher and Managing Editor. This page does not carry a specialist review credit because its publication decision did not require a scientific or clinical conclusion beyond the named material it links to.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.